KRAS and lung cancer: In line with these observations, IL6 blockade significantly reduced tumor development in a KRAS-mutant mouse model of lung cancer by downregulating tumor cell-intrinsic STAT3 activation, tumor cell proliferation, and the expression of angiogenesis markers.